First Time Loading...
M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 090.65 INR -0.09% Market Closed
Updated: May 18, 2024
Section:
 

Relative Value

The Relative Value of one MANKIND stock under the Base Case scenario is 1 098.48 INR. Compared to the current market price of 2 090.65 INR, Mankind Pharma Ltd is Overvalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MANKIND Relative Value
Base Case
1 098.48 INR
Overvaluation 47%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

8.1
P/S
P/S
Price to Sales
8.1
vs History
14
vs Industry
18
Median 3Y
0
Median 5Y
0
Industry
2.5
Forward
7
More Details
43.8
P/E
P/E
Price to Earnings
43.8
vs History
14
vs Industry
10
Median 3Y
0
Median 5Y
0
Industry
23.5
Forward
37.4
More Details
38.9
P/OCF
P/OCF
Price to OCF
38.9
vs History
57
vs Industry
11
Median 3Y
39.4
Median 5Y
39.4
Industry
17.4
More Details
47.2
P/FCFE
P/FCFE
Price to FCFE
47.2
vs History
85
vs Industry
13
Median 3Y
287.2
Median 5Y
287.2
Industry
24.3
More Details
8.9
P/B
P/B
Price to Book Value
8.9
vs History
42
vs Industry
7
Median 3Y
8.7
Median 5Y
8.7
Industry
2.1
More Details
7.8
EV/S
EV/S
Enterprise Value to Sales
7.8
vs History
14
vs Industry
17
Median 3Y
0
Median 5Y
0
Industry
2.6
Forward
6.8
More Details
11.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.3
vs History
14
vs Industry
19
Median 3Y
0
Median 5Y
0
Industry
5.3
More Details
31.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.7
vs History
85
vs Industry
11
Median 3Y
210.7
Median 5Y
210.7
Industry
13.7
Forward
26.8
More Details
37.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
37.6
vs History
14
vs Industry
11
Median 3Y
0
Median 5Y
0
Industry
17.4
Forward
30.6
More Details
37.3
EV/OCF
EV/OCF
Enterprise Value to OCF
37.3
vs History
71
vs Industry
11
Median 3Y
38.8
Median 5Y
38.8
Industry
16.2
More Details
45.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
45.5
vs History
85
vs Industry
11
Median 3Y
70
Median 5Y
70
Industry
18.6
More Details
10.9
EV/IC
EV/IC
Enterprise Value to IC
10.9
vs History
21
vs Industry
10
Median 3Y
9.4
Median 5Y
9.4
Industry
1.9
More Details

Multiples Across Competitors

MANKIND Competitors Multiples
Mankind Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Mankind Pharma Ltd
NSE:MANKIND
837.5B INR 8.1 43.8 31.7 37.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
731.8B USD 20.4 119.2 58.4 66.4
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 16.5 45.1 33.6 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.2B USD 4.3 9.7 11.9 15.6
US
Merck & Co Inc
NYSE:MRK
332.3B USD 5.4 144.1 35.9 58.5
UK
AstraZeneca PLC
LSE:AZN
187.7B GBP 5 37.6 174.5 278.4
CH
Roche Holding AG
SIX:ROG
189B CHF 3.2 16.4 9.3 11
CH
Novartis AG
SIX:NOVN
182.7B CHF 3.4 11.5 8.7 12.7
US
Pfizer Inc
NYSE:PFE
161.7B USD 2.9 -523.3 12.9 20.6
P/E Multiple
Earnings Growth
IN
M
Mankind Pharma Ltd
NSE:MANKIND
Average P/E: 53.4
43.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.2
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.7
-20%
US
Merck & Co Inc
NYSE:MRK
144.1
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -523.3
680%

See Also

Summary
MANKIND intrinsic value, competitors valuation, and company profile.
DCF Valuation
MANKIND stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MANKIND stock valuation using valuation multiples.
Wall Street Estimates
MANKIND price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MANKIND stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.